Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?

Advanced Bladder Cancer Meta-analysis Collaboration, 2003, Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis, Lancet, 361, 1927, 10.1016/S0140-6736(03)13580-5 Advanced Bladder Cancer (ABC) Meta-analysis Collaboration, 2005, Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration, Eur Urol, 48, 202, 10.1016/j.eururo.2005.04.006 Advanced Bladder Cancer Overview Collaboration, 2005, Neoadjuvant chemotherapy for invasive bladder cancer, Cochrane Database Syst Rev Clark, 2013, Bladder cancer, J Natl Compr Canc Netw, 11, 446, 10.6004/jnccn.2013.0059 Lavery, 2014, Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate, J Urol, 191, 898, 10.1016/j.juro.2013.10.142 Rosenblatt, 2012, Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer, Eur Urol, 61, 1229, 10.1016/j.eururo.2011.12.010 Sonpavde, 2009, Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy, Cancer, 115, 4104, 10.1002/cncr.24466 Petrelli, 2014, Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis, Eur Urol, 65, 350, 10.1016/j.eururo.2013.06.049 Grossman, 2003, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer, N Engl J Med, 349, 859, 10.1056/NEJMoa022148 Beukers, 2012, Down-staging (<pT2) of urothelial cancer at cystectomy after the diagnosis of detrusor muscle invasion (pT2) at diagnostic transurethral resection (TUR): is prediction possible?, Virchows Arch, 461, 149, 10.1007/s00428-012-1277-0 Solsona, 2010, Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer, J Urol, 184, 475, 10.1016/j.juro.2010.04.008 Leibovici, 2007, Organ preservation for muscle-invasive bladder cancer by transurethral resection, Urology, 70, 473, 10.1016/j.urology.2007.05.007 Herr, 2001, Transurethral resection of muscle-invasive bladder cancer: 10-year outcome, J Clin Oncol, 19, 89, 10.1200/JCO.2001.19.1.89 Gandhi, 2015, Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes, Urol Oncol, 33, 10.1016/j.urolonc.2015.02.011 Zou, 2004, A modified poisson regression approach to prospective studies with binary data, Am J Epidemiol, 159, 702, 10.1093/aje/kwh090 Kozuki, 2015, Comparison of US Birth Weight References and the International Fetal and Newborn Growth Consortium for the 21st Century Standard, JAMA Pediatr, 169, e151438, 10.1001/jamapediatrics.2015.1438 Fedirko, 2015, Urinary Metabolites of Prostanoids and Risk of Recurrent Colorectal Adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS), Cancer Prev Res (Phila), 8, 1061, 10.1158/1940-6207.CAPR-15-0212 Kirwa, 2014, Residential proximity to major roadways and prevalent hypertension among postmenopausal women: results from the Women′s Health Initiative San Diego Cohort, J Am Heart Assoc, 3, e000727, 10.1161/JAHA.113.000727 Zargar, 2015, Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer, Eur Urol, 67, 241, 10.1016/j.eururo.2014.09.007 Splinter, 1992, The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer—Genitourinary Group, J Urol, 147, 606, 10.1016/S0022-5347(17)37318-4 Nielsen, 2007, Recurrence-free survival after radical cystectomy of patients downstaged by transurethral resection, Urology, 70, 1091, 10.1016/j.urology.2007.08.044 Tollefson, 2012, Downstaging to non-invasive urothelial carcinoma is associated with improved outcome following radical cystectomy for patients with cT2 disease, World J Urol, 30, 795, 10.1007/s00345-012-0855-8 Shariat, 2007, Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy, Eur Urol, 51, 137, 10.1016/j.eururo.2006.05.021 Volkmer, 2005, Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival, Cancer, 104, 2384, 10.1002/cncr.21475 Plimack, 2015, Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer, Eur Urol, 68, 10.1016/j.eururo.2015.07.009 Groenendijk, 2015, ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy, Eur Urol, 69, 384, 10.1016/j.eururo.2015.01.014 Baras, 2015, Identification and validation of protein biomarkers of response to neoadjuvant platinum chemotherapy in muscle invasive urothelial carcinoma, PLoS One, 10, e0131245, 10.1371/journal.pone.0131245